![PRD_000673 PRD_000673](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_000673.svg) | PRD_000673 | Name: | CBZ-ASP-GLU-VAL-azaASP-EP-COO-CH2PH | Formula: | C35 H43 N5 O15 | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
![PRD_000674 PRD_000674](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_000674.svg) | PRD_000674 | Name: | CBZ-ASP-GLU-VAL-azaASP-EP-CO-N(CH2PH)2 | Formula: | C42 H50 N6 O14 | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
![PRD_002314 PRD_002314](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_002314.svg) | PRD_002314 | Name: | INNN(ABU) Cyclic peptide inhibitor | Formula: | C22 H36 N8 O8 | Definition date: | 2019-04-17 | Last modified: | 2023-11-03 |
|
![PRD_000727 PRD_000727](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_000727.svg) | PRD_000727 | Name: | PYOVERDIN G173 Fe Complex | Formula: | C49 H66 Fe N13 O21 | Description: | IN IRON-DEFICIENT CONDITIONS, PSEUDOMONAS
AERUGINOSA SECRETES A MAJOR FLUORESCENT
SIDEROPHORE NAMED PYOVERDIN (PVD),
WHICH AFTER CHELATING IRON(III) IS TRANSPORTED
BACK INTO THE CELL VIA ITS OUTER MEMBRANE RECEPTOR
FPVA. FPVA IS A TONB-DEPENDENT TRANSPORT PROTEIN
AND HAS THE ABILITY TO BIND PVD IN ITS APO-
OR IRON-LOADED FORM. | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
![PRD_000770 PRD_000770](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_000770.svg) | PRD_000770 | Name: | (5S, 8R, 11S)-14-[4-(BENZYLOXY)-4-OXOBUTANOYL]-8-(2-CARBOXYETHYL)-5-(CARBOXYMETHYL)-11-
(1-METHYLETHYL)-3,6,9,12-TETRAOXO-1-PHENYL-2-OXA-4,7,10,13,14-PENTAAZAHEXADECAN-16-OIC ACID | Formula: | C35 H43 N5 O14 | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
![PRD_002350 PRD_002350](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_002350.svg) | PRD_002350 | Name: | INHIBITOR ARC-1415 | Formula: | C55 H106 N30 O8 | Definition date: | 2021-08-04 | Last modified: | 2023-11-03 |
|
![PRD_000781 PRD_000781](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_000781.svg) | PRD_000781 | Name: | Thr-Asp-F-amidine | Formula: | C17 H29 F N6 O7 | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
![PRD_002363 PRD_002363](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_002363.svg) | PRD_002363 | Formula: | C73 H120 N20 O13 | Definition date: | 2020-08-12 | Last modified: | 2023-11-03 |
|
![PRD_000785 PRD_000785](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_000785.svg) | PRD_000785 | Name: | Largazole | Formula: | C21 H29 N4 O4 S3 | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
![PRD_002365 PRD_002365](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_002365.svg) | PRD_002365 | Name: | phazolicin | Formula: | C74 H104 N29 O27 S3 | Definition date: | 2020-08-12 | Last modified: | 2023-11-03 |
|
![PRD_002369 PRD_002369](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_002369.svg) | PRD_002369 | Name: | ecumicin | Formula: | C83 H135 N14 O17 | Definition date: | 2020-05-13 | Last modified: | 2023-11-03 |
|
![PRD_002390 PRD_002390](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_002390.svg) | PRD_002390 | Name: | Papain-like protease peptide inhibitor VIR251 | Formula: | C22 H33 N5 O7 | Definition date: | 2020-05-20 | Last modified: | 2023-11-03 |
|
![PRD_002391 PRD_002391](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_002391.svg) | PRD_002391 | Name: | covalently bound calpain inhibitor II | Formula: | C19 H37 N3 O4 S | Definition date: | 2020-06-17 | Last modified: | 2023-11-03 |
|
![PRD_002392 PRD_002392](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_002392.svg) | PRD_002392 | Name: | UAW246 | Formula: | C25 H36 N4 O6 | Definition date: | 2020-06-17 | Last modified: | 2023-11-03 |
|
![PRD_000814 PRD_000814](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_000814.svg) | PRD_000814 | Name: | N-{[(3R,4R,7S,10R,11R)-3-ethyl-11,15-dihydroxy-3-methyl-10-(methylamino)-6,9-dioxo-7-(propan-2-yl)-2-oxa-5,8-diazabicyclo[10.3.1]hexadeca-1(16),12,14-trien-4-yl]carbonyl}glycine | Formula: | C23 H34 N4 O8 | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
![PRD_002394 PRD_002394](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_002394.svg) | PRD_002394 | Name: | UAW248 | Formula: | C30 H45 N5 O7 | Definition date: | 2020-06-17 | Last modified: | 2023-11-03 |
|
![PRD_000823 PRD_000823](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_000823.svg) | PRD_000823 | Name: | N-propanoyl-D-alanyl-(4R)-4-[(7-bromoisoquinolin-1-yl)oxy]-N-{(1R,2R)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}-L-prolinamide | Formula: | C29 H34 Br N5 O7 S | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
![PRD_000842 PRD_000842](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_000842.svg) | PRD_000842 | Name: | PTA-SFTI INHIBITOR | Formula: | C66 H106 N20 O18 S2 | Description: | Bowman-Birk Inhibitor | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
![PRD_000846 PRD_000846](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_000846.svg) | PRD_000846 | Name: | TRYPSIN INHIBITOR 1 | Formula: | C66 H106 N20 O18 S2 | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
![PRD_000857 PRD_000857](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_000857.svg) | PRD_000857 | Name: | SAH-p53-8 stapled-peptide | Formula: | C96 H151 N26 O25 | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
![PRD_002417 PRD_002417](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_002417.svg) | PRD_002417 | Name: | Ac-VRHA-conh-[4-(4-butyl)-phenoxy-1-phenyl-2-butyl] | Formula: | C43 H66 N10 O7 | Definition date: | 2023-10-25 | Last modified: | 2023-10-25 |
|
![PRD_002443 PRD_002443](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_002443.svg) | PRD_002443 | Name: | SiaLac-amidine-Lys | Formula: | C33 H57 N5 O20 S | Definition date: | 2023-09-27 | Last modified: | 2023-09-27 |
|
![PRD_002387 PRD_002387](https://data.pdbjbk1.pdbj.org/pdbjplus/data/cc/svg/EJG.svg) | PRD_002387 | Name: | tert-butyl N-[5-phenyl-3-(2-phenylethylcarbamoyl)thiophen-2-yl]carbamate | Formula: | C24 H26 N2 O3 S | Definition date: | 2023-09-27 | Last modified: | 2023-09-27 |
|
![PRD_000102 PRD_000102](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_000102.svg) | PRD_000102 | Name: | CYCLIC HEXAPEPTIDE RR(NAL)(NAL)RF | Formula: | C53 H70 N15 O6 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000103 PRD_000103](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_000103.svg) | PRD_000103 | Name: | CYCLIC HEXAPEPTIDE KKWWKF | Formula: | C49 H68 N11 O6 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|